{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:45:07Z","timestamp":1790916307861,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Skin cancer is an overarching label used to classify a variety of cutaneous malignancies. Surgical excision procedures are the commonly used treatments for these lesions; however, the choice to perform operative intervention may be influenced by other factors. Established research and literature suggest that topical treatments limit the need for surgical intervention and its commonly associated adverse effects, including infection and scarring. In addition, the growing indications for the usage of topical therapies in BCC treatment, as well as their increased availability and therapeutic options, allow for their greater applicability in the dermatology clinic. Certain topical therapies have been highlighted in research, especially those targeting basal cell carcinoma (BCC) and actinic keratosis (AK). There is also a clear correlation between cost and treatment outcomes, considering BCC\u2019s ever-growing prevalence and the proportion of excised lesions being reported as malignant. This review will discuss BCC and AK lesion criteria that result in the most successful outcomes using topical treatments, then highlight the various topical treatment options, and finally address their clinical significance moving forward.<\/jats:p>","DOI":"10.3390\/cancers15153927","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:57:33Z","timestamp":1690973853000},"page":"3927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States"],"prefix":"10.3390","volume":"15","author":[{"given":"Isabella J.","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav N.","family":"Pathak","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick H.","family":"Silver","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11864-019-0610-0","article-title":"Diagnosis and Management of Basal Cell Carcinoma","volume":"20","author":"Tanese","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2022.07.005","article-title":"A Bar, Basal Cell Carcinoma","volume":"41","author":"Heath","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaad.2018.02.083","article-title":"Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention","volume":"80","author":"Cameron","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","first-page":"s161","article-title":"Actinic Keratosis: Current Therapies and Insights into New Treatments","volume":"18","author":"Hashim","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of care for the management of actinic keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/09546634.2019.1682504","article-title":"Contemporary management of actinic keratosis","volume":"32","author":"Marghoob","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejps.2015.06.013","article-title":"Topical therapies for skin cancer and actinic keratosis","volume":"77","author":"Haque","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_8","unstructured":"McDaniel, B., Badri, T., and Steele, R.B. (2022). StatPearls, StatPearls Publishing LLC."},{"key":"ref_9","first-page":"CD003412","article-title":"Interventions for basal cell carcinoma of the skin","volume":"11","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary","volume":"118","author":"Peris","year":"2019","journal-title":"Guidel. Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamainternmed.2021.2643","article-title":"Active Surveillance as a Management Option for Low-risk Basal Cell Carcinoma","volume":"181","author":"Linos","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1046\/j.1523-1747.1998.00217.x","article-title":"Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors","volume":"110","author":"Bastiaens","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","first-page":"389","article-title":"Basal cell carcinoma-treatments for the commonest skin cancer","volume":"111","author":"Berking","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaad.2017.02.047","article-title":"Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution","volume":"77","author":"Kuo","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tinelli, M., Ozolins, M., Bath-Hextall, F., and Williams, H.C. (2012). What determines patient preferences for treating low risk basal cell carcinoma when comparingsurgery vs. imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol., 12.","DOI":"10.1186\/1471-5945-12-19"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review","volume":"145","author":"Love","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Verzi, A.E., Micali, G., and Lacarrubba, F. (2021). Line-Field Confocal Optical Coherence Tomography May Enhance Monitoring of Superficial Basal Cell Carcinoma Treated with Imiquimod 5% Cream: A Pilot Study. Cancers, 13.","DOI":"10.3390\/cancers13194913"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2017.11.024","article-title":"Comparing Topical Treatments for Basal Cell Carcinoma","volume":"138","author":"Shaw","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","unstructured":"Nanda, J., and Bermudez, R. (2021). StatPearls, StatPearls Publishing LLC."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0253-7613.161249","article-title":"Imiquimod-Its role in the treatment of cutaneous malignancies","volume":"47","author":"Bubna","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/1203475420931770","article-title":"Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review","volume":"24","author":"Huang","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","article-title":"Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma","volume":"138","author":"Jansen","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_24","unstructured":"Casale, J., and Patel, P. (2021). StatPearls, StatPearls Publishing LLC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.08.045","article-title":"Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis","volume":"87","author":"Neale","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5826\/dpc.0902a01","article-title":"Nonsurgical Options for the Treatment of Basal Cell Carcinoma","volume":"9","author":"Paoli","year":"2019","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jama.2016.3065","article-title":"Actinic Keratosis","volume":"315","author":"Lebwohl","year":"2016","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.36849\/JDD.6704","article-title":"Boada, Classifying Actinic Keratosis: What the Reality of Everyday Clinical Practice Shows Us","volume":"21","author":"Schmitz","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","article-title":"Real-world approach to actinic keratosis management: Practical treatment algorithm for office-based dermatology","volume":"28","author":"Dirschka","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2020.03.127","article-title":"Field cancerization: Treatment","volume":"83","author":"Cornejo","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14740338.2021.1915280","article-title":"Safety of topical interventions for the treatment of actinic keratosis","volume":"20","author":"Koch","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_32","first-page":"616","article-title":"Actinic Keratosis and Cutaneous Squamous Cell Carcinoma","volume":"116","author":"Gutzmer","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized Trial of Four Treatment Approaches for Actinic Keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","first-page":"44","article-title":"Topical imiquimod therapy for actinic keratosis: Is long-term clearance a realistic benefit?","volume":"1","author":"Rosso","year":"2008","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","article-title":"Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: A long-term follow-up study","volume":"140","author":"Stockfleth","year":"2004","journal-title":"Arch. Dermatol."},{"key":"ref_36","first-page":"34","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-uBr","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_38","first-page":"4","article-title":"Tirbanibulin for the Treatment of Actinic Keratosis: A Review","volume":"27","author":"Miller","year":"2022","journal-title":"Ski. Ther. Lett."},{"key":"ref_39","first-page":"S3","article-title":"Profile of Tirbanibulin for the Treatment of Actinic Keratosis","volume":"15","author":"Berman","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1684\/ejd.2021.4092","article-title":"Overview of germline and somatic genetic alterations in basal and squamous cell carcinoma: A review of the current literature","volume":"31","author":"Mazzilli","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_41","first-page":"18","article-title":"Topical therapy in the treatment of actinic keratosis and basal cell carcinoma","volume":"79","author":"Newman","year":"2007","journal-title":"Cutis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-022-00731-x","article-title":"Advances in Topical Treatments of Cutaneous Malignancies","volume":"24","author":"Algarin","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.addr.2019.11.002","article-title":"Topical treatments for skin cancer","volume":"153","author":"Cullen","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1085-5629(03)00047-6","article-title":"Topical and light-based treatments for basal cell carcinoma","volume":"22","author":"Robinson","year":"2003","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_46","first-page":"429","article-title":"Topical and systemic medical treatments of basal cell carcinoma","volume":"150","author":"Sollena","year":"2015","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14728214.2021.1873949","article-title":"Emerging drugs for the treatment of basal cell carcinoma","volume":"26","author":"Herms","year":"2021","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.det.2019.05.003","article-title":"Nonsurgical Treatments for Nonmelanoma Skin Cancer","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36849\/JDD.6632","article-title":"Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review","volume":"21","author":"Mohney","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/CCID.S109531","article-title":"Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%","volume":"9","author":"Bettencourt","year":"2016","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1470-2045(13)70530-8","article-title":"Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): A multicentre, non-inferiority, randomised controlled trial","volume":"15","author":"Ozolins","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ad.2015.04.014","article-title":"Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: A pilot study","volume":"106","year":"2015","journal-title":"Actas Dermosifiliogr."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:24:18Z","timestamp":1760127858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":52,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153927"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153927","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}